Combination Therapy for Patients with Type 2 Diabetes: Repaglinide in Combination with Metformin

Robert G Moses

Disclosures

Expert Rev Endocrinol Metab. 2010;5(3):331-342. 

In This Article

Conclusion

In T2DM, optimal transition from monotherapy to combination therapy is essential to maintain glycemic control and minimize disease progression. Early combination therapy is recommended by current clinical guidelines in order to address both insulin resistance and deficiency in insulin secretion.[4,5] Combination therapy offers a number of advantages related to decreased incidence of adverse events, improved compliance and economic benefits. In addition, FDC medications have demonstrated improved compliance.[83]

Repaglinide and metformin target two different pathophysiological mechanisms underlying T2DM. Combination therapy with repaglinide plus metformin in the form of a single tablet has proven in several clinical studies to be a safe and effective therapeutic option for patients with T2DM with inadequate glycemic control. In addition, single-tablet combination therapy offers enhanced convenience in terms of dosing and patient adherence.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....